Showing 1571-1580 of 2150 results for "".
- Eyenuk Secures $26 Million Series A Funding to Accelerate Global Access to AI-Powered Eye-Screening Technologyhttps://modernod.com/news/eyenuk-secures-26-million-series-a-funding-to-accelerate-global-access-to-ai-powered-eye-screening-technology/2481183/Eyenuk announced it has secured $26 million in a Series A financing round, bringing the company’s total funding to over $43 million. The capital raise was led by AXA IM Alts and was joined by new and existing investors including T&W Medical A/S, A&C Foelsgaard Alternativer ApS,
- Himalayan Cataract Project Appoints Katherine G. Overbey as CEOhttps://modernod.com/news/himalayan-cataract-project-appoints-katherine-g-overbey-as-ceo/2481070/The Himalayan Cataract Project (HCP) has named Katherine G. Overbey (K-T) its new Chief Executive Officer, effective as of October 4, 2022. As HCP enters its 28th year, HCP’s Board of Directors anticipates that Ms. Overbey will guide the organization in its mission to c
- Study: AMD Strongly Associated With Heart Disease and Strokehttps://modernod.com/news/study-blinding-eye-disease-is-strongly-associated-with-heart-disease-and-stroke/2480958/Patients with a specific form of age-related macular degeneration (AMD) are at significant risk for cardiovascular disease and stroke, according to new research from New York Eye and Ear Infirmary of Mount Sinai. This study, published in the July issue of Retina, is the first t
- Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 COMET-2 Study of AR-15512 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-announces-first-participant-dosed-in-the-phase-3-comet-2-study-of-ar-15512-for-the-treatment-of-dry-eye-disease/2480879/Aerie Pharmaceuticals announced that the first participant has been dosed in the phase 3 registrational “COMET-2” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-2 is the first of three trials in t
- Apellis' Pegcetacoplan Showed Continuous Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-pegcetacoplan-showed-continuous-and-clinically-meaningful-effects-at-month-18-in-phase-3-derby-and-oaks-studies-for-geographic-atrophy-ga/2480701/Apellis Pharmaceuticals announced longer-term data from the phase 3 DERBY and OAKS studies, which showed that intravitreal pegcetacoplan, an investigational, targeted C3 therapy, continued to reduce geographic atrophy (GA) lesion growth and demonstrate a favorable safety profile at month 18 for t
- Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucomahttps://modernod.com/news/sight-sciences-launches-dont-wait-for-too-late-awareness-campaign-for-glaucoma/2480649/Sight Sciences announced the launch of its “Don’t Wait for Too Late” educational campaign designed to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an earlier surgical intervention for glaucoma.
- AffaMed Therapeutics Enters into a Licensing Agreement with Hanmi Pharmaceutical for Investigational Dry AMD Treatment in Greater Chinahttps://modernod.com/news/affamed-therapeutics-enters-into-a-licensing-agreement-with-hanmi-pharmaceutical-for-investigational-dry-amd-treatment-in-greater-china/2480540/AffaMed Therapeutics announced that it has entered into a licensing agreement with Hanmi Pharmaceutical Co. Through this partnership, AffaMed obtains exclusive rights to manufacture, develop, and commercialize first-in-class ophthalmic intravitreal injectable product Risuteganib (Luminate) t
- Alcon Inaugurates Company’s Largest European Eye Health Education and Training Center in Barcelonahttps://modernod.com/news/alcon-inaugurates-companys-largest-european-eye-health-education-and-training-centre-in-barcelona/2480404/Alcon officially opened the new Alcon Experience Center (AEC) in Barcelona, one of Europe's largest eye health education and training facilities, offering eye care professionals the opportunity to learn and gain hands-on experience with the latest innovations in ophthalmology and optometry. T
- EyeCare Partners Acquires CEI Vision Partnershttps://modernod.com/news/eyecare-partners-acquires-cei-vision-partners/2480383/EyeCare Partners (ECP) announced it entered into an agreement to acquire CEI Vision Partners (CVP), a network of ophthalmology practices in the Midwest and Mid-Atlantic. Financial terms of the transaction were not disclosed. The deal will create a combined group of more t
- Amidst the COVID-19 Pandemic, Early Intervention Remains an Obstacle for Overall Eye Health Despite Fear of Blindnesshttps://modernod.com/news/amidst-the-covid-19-pandemic-early-intervention-remains-an-obstacle-for-overall-eye-health-despite-fear-of-blindness/2480352/Globally, most adults, 70 percent, don’t plan to get their eyes examined this year, despite acknowledging the critical importance of eye health. These new findings come from a comprehensive, large-scale Johnson & Johnson Vision Global Eye Health Survey announced in advance of World Sigh